Abstract
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.
| Original language | English |
|---|---|
| Pages (from-to) | 631-664 |
| Number of pages | 34 |
| Journal | Medicinal Research Reviews |
| Volume | 39 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2019 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- PI3K
- aging
- anticancer
- kinase inhibitors
- mTOR
Fingerprint
Dive into the research topics of 'Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver